ID
45896
Description
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Dose-Response Relationship, Drug https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000991 The Vanderbilt Electronic Systems for Pharmacogenomic Assessment (VESPA) Project is a large electronic medical record (EMR)- and biobank-based initiative for translational pharmacogenomics discoveries. Key research resources utilized in this effort include the BioVU DNA databank and associated Synthetic Derivative database of clinical information, and software tools developed to identify drugs and clinical events using EHR-derived structured and unstructured ("free text") data. Cohorts include subjects with primarily drug-response phenotypes, and most cases and controls identified include three data types: ICD-9 codes, medication regimens, and medical test results. Advanced informatics methods, such as natural language processing, were also used for some phenotypes. Algorithms used event-sequence analyses to establish temporal relationships between drugs and phenotypes. Both cases and control algorithms excluded records that contained specific comorbidities and were refined to achieve positive predictive value (PPV) 90%. For automated algorithms failing to meet this threshold, manual review was coupled with algorithms to validate that the included cases were true positives. A total of 11,639 subjects met phenotyping criteria for a least one of the 28 phenotypes investigated. Across all phenotypes cases and controls, 90% were reused as either a case or control for a least one other phenotype. Data are deposited for individual phenotypes in the VESPA substudies. *Substudies*:- VESPA: Genome Wide Association Study of Serum Creatinine during Vancomycin Therapy and Vancomycin Pharmacokinetics - phs000894 - VESPA: Genome Wide Study of Clinically Diagnosed Ace Inhibitor Cough - phs000992
Lien
Mots-clés
Versions (1)
- 08/12/2023 08/12/2023 - Simon Heim
Détendeur de droits
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Téléchargé le
8 décembre 2023
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs000991 VESPA: Vanderbilt Electronic Systems for Pharmacogenomic Assessment
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Sample Mapping - Sample Use
- The dataset provides the results of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
- Subject - Consent - Affection Status Information
- Subject - Sample Mapping - Sample Use Information
- Subject - Sample Mapping - Sample Use
- The dataset provides information about the medical history of participants, including diagnoses of respiratory system illnesses, emphysema, and GERD, in addition to information about smoking status (ever/never) and gender/age.
- Sample - Attribute Information
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Sample Mapping - Sample Use
- The dataset provides the results of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
- Subject - Consent - Affection Status Information
- Subject - Sample Mapping - Sample Use Information
- Subject - Sample Mapping - Sample Use
- The dataset provides information about the medical history of participants, including diagnoses of respiratory system illnesses, emphysema, and GERD, in addition to information about smoking status (ever/never) and gender/age.
- Sample - Attribute Information
C0680251 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,2])
C0205369 (UMLS CUI [1,3])
C0031437 (UMLS CUI [1,4])
C5787288 (UMLS CUI [1,5])